

Rotavirus: A Diarrheal Disease in Children

1 contact hour - \$10.00

Expires: Sept 30, 2010

This course was derived from Epidemiology and Prevention of Vaccine Preventable Diseases. Objectives, post test, and editing by JoAnn O'Toole, BSN and Lauren Robertson, BA, MPT.

ATrain Education is an approved provider of continuing nursing education by the Arizona State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

AzNA and ANCC Commission on Accreditation do not approve or endorse any commercial products displayed.

Instructions

1. Read the course material and then complete the following forms:
 - A. Answer Sheet
 - B. Evaluation Learning Activity
 - C. Registration Form
2. If you are not paying by credit card, prepare a check for the amount of the course made out to: *ATrain Education, Inc.*
3. Mail the completed forms and your payment to:
ATrain Education, Inc
5171 Ridgewood Rd
Willits, CA 95490

Once we receive your forms and payment, we will mail (or email, at your request) your completion certificate. If you have any questions, please call or email Info@ATrainCEU.com.

Course Objectives

When you finish this course, you will be able to:

- Describe the characteristics, pathogenesis, and clinical features of rotavirus.
- Describe the complications and clinical diagnosis of rotavirus.
- Outline the epidemiological features of rotavirus including occurrence, transmission, temporal patterns, and communicability.
- Describe current trends in the classification and prevention of rotavirus.
- Discuss the characteristics and efficacy of the rotavirus vaccine.
- Outline the scheduling and use of the rotavirus vaccine in infants.
- Discuss adverse reactions associated with rotavirus vaccination.
- Describe contraindications and precautions to rotavirus vaccination.

Introduction

Diarrheal disease has been recognized in humans since antiquity. Until the early 1970s, a bacterial, viral, or parasitic etiology of diarrheal disease in children could be detected in fewer than 30% of cases. In 1973, Bishop and colleagues observed a virus particle in the intestinal tissue of children with diarrhea by using electron micrography. This virus was subsequently called “rotavirus” because of its similarity in appearance to a wheel (Rota is Latin for wheel).

By 1980, rotavirus was recognized as the most common cause of severe gastroenteritis in infants and young children in the United States. It is now known that infection with rotavirus is nearly universal, with almost all children infected by 5 years of age. Rotavirus is responsible for 20–60 deaths per year in the United States and up to 500,000 deaths from diarrhea worldwide. A vaccine to prevent rotavirus gastroenteritis was first licensed in August 1998 but was withdrawn in 1999 because of its association with intussusception. A second-generation vaccine was licensed in 2006.

Rotavirus Characteristics

Rotavirus is a double-stranded RNA virus of the family *Reoviridae*. The virus is composed of three concentric shells that enclose 11 gene segments. The outermost shell contains two important proteins—VP7, or G-protein, and VP4, or P-protein. VP7 and VP4 define the serotype of the virus and induce neutralizing antibody that is probably involved in immune protection. Five strains of rotavirus (G1–4, G9) account for 90% of isolates from children younger than 5 years in the United States. Of these, the G1 strain accounts for more than 80% of isolates.

Rotavirus is very stable and may remain viable in the environment for weeks or months if not disinfected. Rotaviruses cause infection in many species of mammals, including cows and monkeys. These animal strains are antigenically distinct from those causing human infection, and they rarely cause infection in humans.

Pathogenesis

The virus enters the body through the mouth. Viral replication occurs in the villous epithelium of the small intestine. Replication outside the small intestine and systemic spread of the virus (viremia) are believed to be uncommon in immunocompetent persons. Infection may result in decreased intestinal absorption of sodium, glucose, and water, and decreased levels of intestinal lactase, alkaline phosphatase, and sucrase activity, and may lead to isotonic diarrhea.

Rotavirus Pathogenesis

- Entry through mouth
- Replication in epithelium of small intestine
- Replication outside intestine and viremia uncommon
- Infection leads to isotonic diarrhea

The immune correlates of protection from rotavirus are poorly understood. Serum and mucosal antibodies against VP7 and VP4 are probably important for protection from disease. Cell-mediated immunity probably plays a role in recovery from infection and in protection. Recovery from a first rotavirus infection usually does not lead to permanent immunity. After a single natural infection, 40% of children are protected against any subsequent rotavirus infection, 75% are protected against rotavirus diarrhea, and 88% are protected against severe diarrhea.

Reinfection can occur at any age. Subsequent infections confer progressively greater protection and are generally less severe than the first. Recurrent rotavirus infections affect persons of all ages. Recurrent infections are usually asymptomatic or result in mild diarrhea that may be preceded or accompanied by vomiting and low-grade fever.

Clinical Features

The incubation period for rotavirus diarrhea is 1–3 days. The clinical manifestations of infection vary and depend on whether it is the first infection or reinfection. Infection may be asymptomatic, may cause self-limited watery diarrhea, or may result in severe dehydrating diarrhea with fever and vomiting. The first infection after 3 months of age is generally the most severe. Up to one-third of infected children may have a temperature greater than 102°F (39°C). The gastrointestinal symptoms generally resolve in 3–7 days.

The clinical features and stool characteristics of rotavirus diarrhea are nonspecific, and similar illness may be caused by other pathogens. As a result, confirmation of a diarrheal illness as rotavirus requires laboratory testing.

Complications

Rotavirus infection in infants and young children can lead to severe diarrhea, dehydration, electrolyte imbalance, and metabolic acidosis. Immunodeficient children may have more severe or persistent disease and may have evidence of abnormalities in multiple organ systems, particularly the kidney and liver.

Laboratory Diagnosis

The most widely available method for confirmation of rotavirus infection is detection of rotavirus antigen in stool by enzyme immunoassay (EIA). Several commercial test kits are available that detect an antigen common to human rotaviruses. These kits are simple to use, inexpensive, and very sensitive. Other techniques (such as electron microscopy, reverse transcription polymerase chain reaction, nucleic acid hybridization, sequence analysis, and culture) are used primarily in research settings. Rotavirus antigen has also been identified in the serum of patients 3–7 days after disease onset, but at present, routine diagnostic testing is based primarily on testing of fecal specimens.

Epidemiology

The factors determining the frequency and distribution of Rotavirus in human communities are as follows.

Occurrence

Rotavirus occurs throughout the world. The prevalence of rotavirus strains varies by geographic area, and strains not included in the vaccine are present in some parts of the world.

Reservoir

The reservoir of rotavirus is the gastrointestinal tract and stool of infected humans. Although rotavirus infection occurs in many nonhuman mammals, transmission of animal rotaviruses to humans is believed to be rare and probably does not lead to clinical illness. Although immunodeficient persons may shed rotavirus for a prolonged period, a true carrier state has not been described.

Transmission

Rotaviruses are shed in high concentration in the stool of infected persons. Transmission is by fecal-oral spread, both through close person-to-person contact and by fomites (such as toys and other environmental surfaces contaminated by stool). Rotaviruses are also probably transmitted by other modes such as respiratory droplets and fecal contamination of food and water.

Temporal Pattern

In temperate climates, disease is more prevalent during cooler months. In the United States, annual epidemic peaks usually progress from the Southwest during November and December and spread to the Northeast by April and May. The reason for this seasonal pattern is unknown. In tropical climates, the disease is less seasonal than in temperate areas.

Communicability

Rotavirus is highly communicable, as evidenced by the nearly universal infection of children by age 5 years. Infected persons shed large quantities of virus in their stool beginning 2 days before the onset of diarrhea and for up to 10 days after onset of symptoms. Rotavirus may be detected in the stool of immunodeficient persons for more than 30 days after infection. Spread within families, institutions, hospitals, and childcare settings is common.

| Rotavirus Epidemiology | |
|-------------------------------|--------------------------------------|
| Reservoir | Human |
| Transmission | Fecal-oral, fomites |
| Temporal pattern | Fall and winter (temperate areas) |
| Communicability | 2 days before to 10 days after onset |

Secular Trends in the United States

Rotavirus infection is not nationally notifiable in the United States. Estimates of incidence and disease burden are based on special surveys, cohort studies, and hospital discharge data.

Rotavirus infection is nearly universal. An estimated 2.7 million cases occur each year in the United States alone, and 95% of children experience at least one rotavirus infection by age 5 years. The incidence of rotavirus is similar in developed and developing countries, suggesting that improved sanitation alone is not sufficient to prevent the infection.

Infants younger than 3 months of age have relatively low rates of rotavirus infection, probably because of passive maternal antibody, and possibly breastfeeding. The incidence of clinical illness is highest among children 3 to 35 months of age. Rotavirus infection of adults is usually asymptomatic but may cause diarrheal illness.

In the United States, rotaviruses are responsible for 5%–10% of all gastroenteritis episodes among children younger than 5 years of age. However, they are the most common cause of severe diarrheal disease and account for a higher proportion of severe episodes leading to clinic or hospital visits. Rotavirus accounts for 30%–50% of all hospitalizations for gastroenteritis among U.S. children younger than 5 years of age, and more than 70% of hospitalizations for gastroenteritis during the seasonal peaks.


Rotavirus infection is responsible for more than 400,000 physician visits, more than 200,000 emergency department (ED) visits, 55,000–70,000 hospitalizations each year, and 20–60 deaths. Annual direct and indirect costs are estimated at approximately \$1 billion, primarily due to the cost of time lost from work to care for an ill child.

Groups at increased risk for rotavirus infection are those with increased exposure to virus. This includes children who attend child care centers, children in hospital wards (nosocomial rotavirus), caretakers and parents of children in child care or hospitals, and children and adults with immunodeficiency-related diseases (e.g., Severe Combined Immunodeficiency Disease (SCID), HIV, bone marrow transplant).

Rotavirus Vaccine

The first rotavirus vaccines were derived from either bovine (cow) or rhesus (monkey) origin. Studies demonstrated that these live oral vaccines could prevent rotavirus diarrhea in young children, but efficacy varied widely. Because immunity to G (VP7) and P (VP4) proteins was associated with disease protection and recovery, new live virus vaccines were developed that incorporated G proteins or both G and P proteins for each of the predominant serotypes. The process by which these vaccine viruses were created is called genetic reassortment. Tissue culture cells were infected with two different rotavirus strains—a nonhuman “parent” strain and a human strain that contained the VP7 gene of a predominant serotype. When the viruses replicated, the offspring viruses had various combinations of gene segments from the two strains. Offspring were selected that contained the gene segment coding for a human G (VP7) serotype.

Rotavirus Vaccine (Rota)



The remainder of the gene was identical to the parent nonhuman strain. By this process, viruses—known as reassortants—were developed that expressed human G1, G2, G3, and G4 serotypes of the VP7 antigen.

In 1998, a rhesus-based tetravalent rotavirus vaccine (RRVTV, RotaShield) was licensed and recommended for routine immunization of U.S. infants. However, RRV-TV was withdrawn from the U.S. market within one year of its introduction because of its association with intussusception. The risk of intussusception was most elevated (more than a 20-fold increase) within 3–14 days after receipt of the first dose of RRV-TV, with a smaller (approximately 5-fold) increase in risk within 3–14 days after the second dose. Overall, the risk associated with the first dose of RRV-TV was estimated to be about one case per 10,000 vaccine recipients. Some researchers have suggested that the risk of intussusception associated with RRV-TV was age-dependent and that the absolute number of intussusception events, and possibly the relative risk of intussusception associated with

the first dose of RRV-TV, increased with increasing age at vaccination.

Characteristics

In February 2006, the Food and Drug Administration approved a new rotavirus vaccine (Rota), RotaTeq, produced by the Merck Vaccine Division. RotaTeq is a live, oral vaccine that contains five reassortant rotaviruses developed from human and bovine parent rotavirus strains. Four reassortant rotaviruses express one of the outer proteins (G1, G2, G3, or G4) from the human rotavirus strain and the attachment protein (P7[5]) from the bovine rotavirus parent strain. The fifth reassortant virus expresses the attachment protein from the human rotavirus strain and the outer protein (G6) from the bovine rotavirus parent strain. The parent bovine rotavirus strain Wistar Calf 3 (WC3) was isolated in 1981 from a calf with diarrhea in Chester County, Pennsylvania. The virus was passaged 12 times in African green monkey kidney cells. The reassortants are propagated in Vero cells using standard tissue culture techniques.

RotaTeq consists of the five human–bovine reassortants suspended in a solution of buffer (sodium citrate and phosphate) and stabilizer (sucrose). Each 2-mL vial of vaccine contains approximately 2×10^6 infectious units of each of the five reassortant strains. The vaccine formulation contains sucrose, sodium citrate, sodium phosphate monobasic monohydrate, sodium hydroxide, polysorbate 80, and tissue culture media. Trace amounts of fetal bovine serum might be present. The vaccine contains no preservatives or thimerosal.

Fecal shedding of vaccine virus was evaluated in a subset of persons enrolled in the phase III trials. Vaccine virus was shed by 32 (8.9%) of 360 infants after dose 1, but none of 249 and 385 infants after doses 2 and 3, respectively. Shedding was observed as early as 1 day and as late as 15 days after a dose. The potential for horizontal transmission of vaccine virus was not assessed through epidemiologic studies.

Immunogenicity and Vaccine Efficacy

Phase III clinical trials of Rotateq immunogenicity and efficacy have involved more than 70,000 infants 6–12 weeks of age in 11 countries. The immune correlates of protection from rotavirus infection and disease are not fully understood. In clinical trials, a rise in titer of rotavirus group-specific serum IgA antibodies was used as one of the measures of immunogenicity. Sera were collected before vaccination and approximately 2 weeks after the third dose. Seroconversion was defined as a threefold or greater rise in antibody titer from baseline. Seroconversion rates for IgA antibody to rotavirus were 93%–100% among 439 vaccine recipients versus 12%–20% among 397 placebo recipients.

After completion of a three-dose regimen, the efficacy of rotavirus vaccine against rotavirus gastroenteritis of any severity was 74%, and against severe rotavirus gastroenteritis (defined by severity of fever, vomiting, diarrhea and changes in behavior) was 98%. Vaccine efficacy varied by rotavirus serotype.

In a large study, the efficacy of rotavirus vaccine against rotavirus gastroenteritis requiring office visits was evaluated among 5,673 persons, and efficacy against rotavirus gastroenteritis requiring ED visits and hospitalizations was evaluated among 68,038 persons during the first 2 years of life. Rotavirus vaccine reduced the incidence of office visits by 86%, ED visits by 94%, and hospitalizations for rotavirus gastroenteritis by 96%. The efficacy of fewer than three doses is not known.

Duration of Immunity

The duration of immunity from rotavirus vaccine is not known. At least one clinical trial has demonstrated that protection lasts through at least 2 rotavirus seasons, although efficacy was somewhat lower in the second season than in the first.

Vaccination Schedule and Use

The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination of all infants without contraindications with three doses of rotavirus vaccine administered orally at ages 2, 4, and 6 months. The minimum age for the first dose is 6 weeks. The first dose should be administered between 6 and 12 weeks of age (that is, until age 13 weeks). Vaccination should not be initiated for infants older than 12 weeks because of insufficient data on safety of the first dose of rotavirus vaccine in older infants.

All three doses should routinely be separated by 2 months. However, the minimum interval between doses may be as short as 4 weeks if an accelerated schedule is required. Special effort should be made to immunize infants before the winter rotavirus season, and the use of an accelerated schedule may facilitate this effort.

The maximum age for any dose of rotavirus vaccine is 32 weeks because of insufficient data on the safety and efficacy of rotavirus vaccine in infants after this age. Rotavirus vaccine should not be administered on or after age 32 weeks, even if fewer than three doses have been administered.

Rotavirus vaccine may be administered simultaneously with all other vaccines that are routinely given at the same ages (hepatitis B, DTaP, IPV, Hib, PCV). Breastfeeding does not appear to diminish immune response to three doses of vaccine. Children who are being breastfed should be vaccinated on schedule.

Infants who have recovered from documented rotavirus infections may not be immune to all five serotypes present in the vaccine. These infants should complete the three-dose vaccination series by 32 weeks of age. Data on the safety of administering a dose higher than the recommended dose, or on the efficacy of a partial dose are very limited. As a result, a second dose of rotavirus vaccine should not be administered to an infant who regurgitates, spits out some or all of the dose, or vomits during or after administration of vaccine. The infant should receive the remaining recommended doses, if needed, on the usual schedule.

Adverse Reactions Following Vaccination

Following are possible adverse reactions that can occur following a vaccination.

Intussusception

The risk for intussusception was evaluated in more than 70,000 infants enrolled in phase III efficacy trials. During the 42 days after vaccination six cases of intussusception were observed in the vaccine group and five cases in the placebo group. There was no evidence, regardless of dose, of clustering of cases of intussusception within 7–14 days postvaccination, the period of greatest risk for intussusception associated with the RRV-TV vaccine. For the 1-year follow-up period after administration of the first dose, 13 cases of intussusception were observed in the vaccine group and 15 cases of intussusception in the placebo group (relative risk: 0.9).

Reports of intussusception among rotavirus vaccine have been received by the Vaccine Event Reporting System (VAERS). However, the number of reports is not greater than are expected by chance.

Other Adverse Events

In the 42-day period after vaccination, vaccine recipients had a small increased risk of certain symptoms compared with placebo recipients, including vomiting (15% versus 14%), diarrhea (24% versus 21%), nasopharyngitis (7% versus 6%), otitis media (15% versus 13%), bronchospasm (1.1% versus 0.7%).

Contraindications and Precautions to Vaccination

Rotavirus vaccine is contraindicated for infants who are known to have had a severe allergic (anaphylactic) reaction to a vaccine component or following a prior dose of vaccine. Precaution conditions are those that may increase the chance of a vaccine adverse reaction or reduce the efficacy of the vaccine.

In general, infants with precautions to vaccination, described below, should not receive the vaccine until the condition improves unless the benefit of vaccination outweighs the risk of an adverse reaction. The decision to withhold rotavirus vaccine if a precaution is present means that the infant will be infected with wild-type rotavirus, which is more likely to cause severe illness than the attenuated vaccine virus.

Clinicians should consider the potential risks and benefits of administering rotavirus vaccine to infants with known or suspected altered immunocompetence. Children and adults who are immunocompromised because of congenital immunodeficiency, hematopoietic transplantation, or solid organ transplantation sometimes experience severe, prolonged, and even fatal rotavirus gastroenteritis. However, no safety or efficacy data are available regarding administration of rotavirus vaccine to infants who are or are potentially immunocompromised due to either disease or drugs (including HIV infection or high-dose systemic corticosteroids for more than 2 weeks). Data from the clinical trials are insufficient to support administration of rotavirus vaccine to infants with indeterminate HIV status who are born to mothers with HIV/AIDS.

The effect of recent receipt of an antibody-containing blood product on the efficacy of rotavirus vaccine is unknown. However, ACIP recommends deferral of vaccination for infants who have received an antibody-containing product, including blood and immunoglobulin, for 6 weeks after receipt of the blood product. However, if the 6-week deferral would cause the first dose of rotavirus vaccine to be scheduled at an age older than 12 weeks, a shorter deferral interval should be used to ensure the first dose is administered before age 13 weeks.

Usually, rotavirus vaccine should not be administered to infants with acute, moderate to severe gastroenteritis or other acute illness until the condition improves. However, infants with mild acute gastroenteritis can be vaccinated, particularly if the delay in vaccination will delay the first dose of vaccine until 13 weeks of age or older.

The safety and efficacy of rotavirus vaccine in children with pre-existing chronic gastrointestinal (GI) conditions, such as congenital malabsorption syndromes, Hirschsprung disease, or short-gut syndrome, has not been determined. The decision to vaccinate children with these conditions must be made on a case-by-case basis.

Additional postlicensure surveillance data are required to confirm that rotavirus vaccine is not associated with intussusception at a lower rate than would have been detected in prelicensure trials. In addition, data suggest that infants with a history of intussusception might be at higher risk for a repeat episode than other infants. Therefore, until postlicensure data on the safety of rotavirus vaccine are available, the risks for and the benefits of vaccination should be considered when vaccinating infants with a previous episode of intussusception.

Practitioners should consider the potential risks for and benefits of vaccinating preterm infants against rotavirus. Limited data suggest that preterm infants are at increased risk for hospitalization from viral gastroenteritis during their first year of life. In clinical trials, the safety and efficacy of rotavirus vaccine appear to be similar for preterm and term infants, although a relatively small number of preterm infants have been evaluated. The lower level of maternal antibody to rotaviruses in very low birthweight, preterm infants theoretically could increase the risk for adverse reactions from rotavirus vaccine. ACIP supports vaccination of preterm born infants if they are at least 6 weeks of age, are being or have been discharged from the hospital nursery, and are clinically stable. Until further data are available, ACIP considers that the benefits of vaccination of preterm infants with rotavirus vaccine outweigh the theoretical risks.

Infants living in households with persons who have or are suspected of having an immunodeficiency disorder or impaired immune status can be vaccinated. The majority of experts believe the protection of the immunocompromised household member afforded by vaccination of young children in the household outweighs the small risk for transmitting vaccine virus to the immunocompromised household member and any subsequent theoretical risk for vaccine virus–associated disease. To minimize potential virus transmission, all members of the household should employ measures such as good handwashing after contact with the feces of the vaccinated infant (e.g., after changing a diaper). Infants living in households with a pregnant woman can be vaccinated.

Vaccine Storage and Handling

RotaTeq is provided in a squeezable plastic dosing tube with a twist-off cap designed to allow for the vaccine to be administered directly to infants by mouth. Each tube contains a single 2-mL dose of the vaccine as a liquid buffered stabilizer solution that is pale yellow in color but might have a pink tint. This formulation protects the vaccine virus from gastric acid and stabilizes the vaccine. The vaccine must be stored at refrigerator temperatures (35°–46°F [2°–8°C]).

The shelf life of properly stored vaccine is 24 months. The vaccine must not be frozen. RotaTeq should be administered as soon as possible after being removed from refrigeration. Additional information on stability under conditions other than those recommended is available from the manufacturer at 800-637-2590.

Rotavirus Surveillance

Rotavirus gastroenteritis is not a reportable disease in the United States, and testing for rotavirus infection is not always performed when a child seeks medical care for acute gastroenteritis. Establishing rotavirus disease surveillance systems that are adequately sensitive and specific to document the effectiveness of vaccination programs will be necessary.

National surveillance systems for rotavirus infections include review of national hospital discharge databases for rotavirus-specific or rotavirus-compatible diagnoses and reports of rotavirus isolation from a sentinel system of laboratories and surveillance in three sites that participate in the New Vaccine Surveillance Network. At state and local levels, additional surveillance efforts at sentinel hospitals or by review of hospital discharge databases will be necessary to monitor the impact of the vaccination program. Special studies (e.g., case-control studies and retrospective cohort studies) will be needed to confirm the effectiveness of rotavirus vaccine in routine programmatic use.

Reference

Centers for Disease Control and Prevention. *Epidemiology and Prevention of Vaccine-Preventable Diseases*. Atkinson W, Hamborsky J, McIntyre L, Wolfe S, eds. 10th ed. 2nd printing, Washington DC: Public Health Foundation, 2008.

Post Test

Circle one answer per question.

1. The most common cause of severe gastroenteritis in infants and young children in the United States is:
 - a) *H. pylori*
 - b) Influenza
 - c) Rotavirus
 - d) *E. coli*

2. The rotavirus:
 - a) Is unstable and remains viable in the environment for no more than 2 hours.
 - b) Causes infection in many species of mammals including cows and monkeys, which is frequently transmitted to humans.
 - c) Rarely causes illness in the United States.
 - d) Consists of 5 strains which account for 90% of isolates from children younger than 5 years of age in the United States.

3. The rotavirus enters the body through the mouth and is a common cause of viremia.
 - a) True
 - b) False

4. Rotavirus infection:
 - a) Leads to permanent immunity after the initial infection.
 - b) Never occurs past the age of five.
 - c) Confers progressively greater protection from illness with subsequent infections.
 - d) Does not confer immunity and therefore subsequent infections can be as severe as the initial infection.

5. The clinical manifestations of rotavirus infection:
 - a) Are very specific and distinct and do not require laboratory testing.
 - b) May include severe diarrhea, dehydration, electrolyte imbalance and metabolic acidosis.
 - c) Are generally not severe in a first infection after 3 months of age.
 - d) Include gastrointestinal symptoms which usually resolve in 2–3 weeks.

6. Rotavirus is a highly communicable disease that is:
 - a) Often spread by carriers of the disease who are asymptomatic.
 - b) Most often spread by the fecal-oral route, both through close person-to-person contact and by fomites.
 - c) Spread by contact with the blood of an infected person.
 - d) Mainly seen in Africa and Asia.

7. Infection with rotavirus is:

- a) The most common cause of severe diarrheal disease in children younger than 5 years of age.
- b) Common among breast-fed children younger than 3 months caused by transmission of the virus through breast milk.
- c) Usually severe in adults due to waning immunity to the virus.
- d) The most common cause of pneumonia in children.

8. The rhesus-based tetravalent rotavirus vaccine was withdrawn from the U.S. market for routine immunization of infants because of its association with: D

- a) Pneumonia
- b) Meningitis
- c) Influenza
- d) Intussusception

9. Vaccination for rotavirus:

- a) Has not been proven effective and is not recommended for use in the United States.
- b) Must be started after 32 weeks of age and given in 3 doses separated by 2 months.
- c) Provides life-long immunity.
- d) Reduced hospitalization during the first 2 years of life for rotavirus gastroenteritis by 96% in a large study.

10. The risk of intussusception in more than 70,000 infants enrolled in phase III efficacy trials of the RotaTeq vaccine proved to be no greater than that expected by chance.

- a) True
- b) False

11. Contraindications to administration of the rotavirus vaccine include:

- a) Acute, moderate gastroenteritis
- b) Severe allergic reaction to a vaccine component or following a prior dose of vaccine
- c) A household member who is immunocompromised
- d) A household member who is pregnant

12. RotaTeq vaccine:

- a) Is administered in 3 intramuscular doses
- b) Is administered in 2 oral doses that are 3 months apart
- c) Should be initiated after 12 weeks of age
- d) Should be administered orally in 3 doses that are 2 months apart

Answer Sheet

Rotavirus: A Diarrheal Disease in Children

Name (Please print your name) _____

Date: _____

Passing score is 80%

1. _____
2. _____
3. _____
4. _____
5. _____
6. _____
7. _____
8. _____
9. _____
10. _____
11. _____
12. _____

Evaluation Learning Activity

Please answer each of the following questions. Questions with an asterisk (*) are required.

* 1. This course met the goals and learning objectives.

Yes No

* 2. The author was well prepared to write about the content in a way that facilitated my learning.

Yes No

* 3. This course was free from commercial bias.

Yes No

* 4. The learning activity met my continuing education needs.

Yes No

* 5. The learning activity took me 60 minutes per contact hour.

(If you answer "No", please enter the total time it took to finish the course, test, and evaluation.)

Yes

No. How long did it take to finish the course, test, and evaluation? _____

6. My professional educational level is (check one):

Nursing

Nurse Aide LVN/LPN RN (diploma) RN (AD)

BSN MSN Nurse Practitioner / Advanced Practice Nurse

PhD / DNSc

Therapy

OT Aide COTA OT MOT OTD

PT Aide PTA PT MPT MSPT DPT PhD

Other (please specify): _____

(continued on next page)

7. I heard about ATrain Education from:

- Search engine
- Government or Board website
- Friend
- Advertisement
- Returning customer
- Other _____

8. I found the ATrainCEU.com website easy to use:

- Yes
- No

9. Comments or suggestions (optional): _____

Registration Information

Please answer all of the following questions (*required).

*Name: _____

*Address: _____ City _____ State ____ Zip _____

*Phone: _____

*Professional Designation: _____

*License Number and State: _____

*Please e-mail my certificate: Yes No

*Email: _____

(Note: If you request an email certificate we will not send a copy of your certificate by US Mail.)

Payment Options

You may pay by credit card or by check.

Fill out this section only if you are **paying by credit card**.

1.0 contact hours - \$10.00

Fill out this section if paying by credit card

Name _____

Address: (if different) _____ City _____ State ____ Zip _____

Card type: Visa MC American Express Discover

Card number _____

Expiration date _____

Test Completion and Mailing Instructions

1. Complete all forms:

- Answer Sheet
- Evaluation Learning Activity
- Registration Form (this page)

2. If you are **paying by check**, prepare a check for \$10 made out to ATrain Education, Inc.

3. Mail the completed forms and your payment to:

ATrain Education, Inc
5171 Ridgewood Rd
Willits, CA 95490

Once we receive your forms and payment, we will mail (or email, if you request it) your certificate of completion. If you have any questions or concerns, please call or contact us at info@ATrainCEU.com. And thanks for taking the ATrain!